NCT03357874View on ClinicalTrials.gov

TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.

PHASE3CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

October 28, 2018

Primary Completion Date

January 1, 2023

Study Completion Date

July 18, 2023

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Clopidogrel

600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).

DRUG

Ticagrelor

patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).

Trial Locations (1)

13354

APHM, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER

NCT03357874 - TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome. | Biotech Hunter | Biotech Hunter